Literature DB >> 3497715

Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.

V S Byers, M V Pimm, P J Scannon, I Pawluczyk, R W Baldwin.   

Abstract

Immunotoxin constructed by conjugating ricin A chain to monoclonal antibody 791T/36 specifically inhibits growth of human tumor xenografts which express the gp72 antigen recognized by the antibody component. Dose schedule tests showed that the major response was obtained during the first 5 days of treatment and further prolonged treatment did not improve therapy. Expression of gp72 antigen on tumor cells derived from xenografts in immunotoxin-treated mice was not markedly altered indicating that treatment did not lead to the expansion of tumor antigen deficient tumor cells. The experiments indicate that treatment for short duration with immunotoxin may be the most effective protocol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497715

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

2.  Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.

Authors:  L G Durrant; V S Byers; P J Scannon; R Rodvien; K Grant; R A Robins; R A Marksman; R W Baldwin
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

Review 3.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 4.  Immunotherapy with monoclonal antibodies in metastatic melanoma.

Authors:  T A Steffens; D F Bajorin; A N Houghton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

5.  Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.

Authors:  L Cattel; L Delprino; P Brusa; F Dosio; P M Comoglio; M Prat
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 6.  Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives.

Authors:  Daniele Mercatelli; Massimo Bortolotti; Alberto Bazzocchi; Andrea Bolognesi; Letizia Polito
Journal:  Biomedicines       Date:  2018-02-10

Review 7.  Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment.

Authors:  Duoli Xie; Zhuqian Wang; Jie Li; De-An Guo; Aiping Lu; Chao Liang
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.